Stints
Stints: Heart Disease Treatment Without Surgery
A stint is a tube of metal mesh that is used to keep an artery opening during angioplasty. The stint is first put over a balloon catheter and moved into the area that is blocked. The balloon is then inflated while the stint expands and locks into places forming a temporary frame.
Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
According to Millennium Research Group's (MRG's) European Markets for Peripheral Vascular (PV) Devices 2009 report, rapid growth in the number of endovascular procedures that treat lower extremity peripheral artery disease in Europe is being fueled by positive clinical trial results, increased competitor focus, and the release of new drug-eluting devices for these indications. Combined, these factors will drive the markets for lower extremity PV stents and percutaneous transluminal angioplasty (PTA) balloon catheters to reach combined revenues in excess of $180 million by 2013.
FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
VANCOUVER, May 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a drug-eluting stent.
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Boston Scientific Corporation (NYSE: BSX) today announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The TAXUS Element Stent features a new platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.
Related Searches
Related Articles
Worldwide Sales of Drug-Eluting Stents to Clock US$5.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Drug-eluting stents, a breakthrough technology in the interventional cardiology field, are designed to reduce restenosis and thereby the requirement for repeated revascularizations. Innovative products and higher reimbursement are expected to pep up growth and expand drug-eluting stents market to corner US$5.7 billion by 2015. On the negative side, adverse effects such as in-stent thrombosis by the use of drug-eluting stents represents the most inhibiting market factor.
Visionary: Benigno "Ninoy" Aquino
Ninoy Aquino developed his vision in life - to see a prosperous Philippines - early. Born to a prosperous landed family, Aquino was an exemplary student whose tertiary education was interrupted by a journalist stint in Korea for the Manila Times, a popular Philippine newspaper. Aquino's career building goals soon started to revolve around public service, as he entered government service for then-president Ramon Magsaysay. Soon, he was a noted peacemaker who sped along the government's peace process.
Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
VANCOUVER, May 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Develop your domains with WhyPark. WhyPark provides all the Design, Content, and Ads for free to start a website. You can add content of your own and use your own creativity and skills to further enhance your website.